MEGGLE raises Asian profile at CPhI Jakarta

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) has used CPhI South East Asia expo in Indonesia to present its world-leading range of lactose-based pharmaceutical excipients to a rapidly-expanding Asian market.

The MEGGLE Excipients & Technology team has exhibited at a special booth on the stand of its Indonesian distributors P.T. Menjangan Sakti at booth B10 at the Jakarta International Expo Center.

Innovative lactose excipients

The MEGGLE stand displayed a wide range of the company’s innovative lactose-based products and co-processed excipients including the ground-breaking Tablettose® agglomerated lactose, DuraLac® H anhydrous lactose and FlowLac® spray-dried alpha-lactose monohydrates, all of which have helped revolutionize direct compression tableting.

Video screens on the stand provided visitors with insights into MEGGLE’s rigorous production standards, advanced technology and pioneering research work.

Return to Jakarta

This is a return to Jakarta for MEGGLE, which attended the 2016 CPhI SEA show.

“CPHI SEA 2017 has been a well-organised show by UBM. Apart from engaging customers and prospective clients at the booth, I had the opportunity to hold a seminar during the show, allowing Meggle to present our products in a different format. Exhibiting at P.T. Menjangan Sakti’s booth significantly boosted our local presence and brand awareness,” commented Dr. Siang Meng Chua, Director of MEGGLE Singapore (PTE) Ltd., who led the company’s team at CPhI SEA 2017.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s foremost experts in lactose and its applications in pharmaceuticals.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary ream of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for implementation in customer applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose powder and lactose monohydrate for outstanding compression and flow properties and RetaLac®, the first co-processed excipient to use a hypromellose-lactose base for sustained release formulations.

About CPhI SEA 2017

CPhI South East Asia (SEA) is one of the most recent additions to UBM-organized franchise, extending the same ‘four in one’ format that has made these pharma industry events so successful to the ASEAN life sciences market.

The event co-locates four shows under one roof, with the CPhI show providing a marketplace for pharmaceutical ingredients manufacturers, suppliers and buyers while P-MEC South East Asia showcases machinery and laboratory equipment, InnoPack focuses on packaging and drug delivery systems and ICSE connects with outsourced solution providers, including clinical trials, contract research, contract manufacturing, biotech, IT, analytical services, packaging services and logistics.

CPhI SEA 2017 will be three-day event, opening March 22 at the Jakarta International Expo center in the Indonesian capital. It is expected to attract some 5,500 attendees and exhibitors from more than 20 countries across the region as well as from Europe and North America.

The event is organized by UBM Live. More information at: http://www.cphi.com/sea/